AR031067A1 - Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma. - Google Patents

Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma.

Info

Publication number
AR031067A1
AR031067A1 ARP000101511A ARP000101511A AR031067A1 AR 031067 A1 AR031067 A1 AR 031067A1 AR P000101511 A ARP000101511 A AR P000101511A AR P000101511 A ARP000101511 A AR P000101511A AR 031067 A1 AR031067 A1 AR 031067A1
Authority
AR
Argentina
Prior art keywords
yohimbine
arginine
pharmaceutically acceptable
acceptable salt
sachet
Prior art date
Application number
ARP000101511A
Other languages
English (en)
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc filed Critical Nitromed Inc
Publication of AR031067A1 publication Critical patent/AR031067A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D459/00—Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un sachet para prevenir o tratar disfunciones sexuales comprende una composicion para administrar una dosis unica de una composicion que comprende L-arginina y/o una sal farmacéuticamente aceptable de la misma y yohimbina y/o una sal farmacéuticamente aceptable de la misma. La L-arginina es un compuesto que aumenta in vivo el oxido nítrico endogeno o el factor relajante derivado de endotelio o es un sustrato para la oxido nítrico sintetasa y la yohimbina es el antagonista de los factores alfa-adrenérgicos. Una tableta y polvo efervescente de administracion oral comprenden L-arginina y/o una sal farmacéuticamente aceptable de la misma en una cantidad comprendida entre aproximadamente 1 g y aproximadamente 10g en base a la L-arginina en su forma de base libre y yohimbina o una sal farmacéuticamente aceptable de la misma en una cantidad comprendida entre aproximadamente 1 mg y aproximadamente 18 mg en base a la yohimbina bajo la forma de base libre. Las composiciones para la administracion oral no tienen los efectos secundarios indeseables que presentan los agentes habitualmente usados. El uso de la L-arginina y/o una sal farmacéuticamente aceptable de la misma, en una cantidad comprendida entre aproximadamente 1g y aproximadamente 10 g basada en L-arginina o yohimbina bajo sus formas de bases libres, o una sal farmacéuticamente aceptable de las mismas en una cantidad comprendida entre aproximadamente 1 mg y aproximadamente 18 mg basada en la forma de base libre de la yohimbina, para la produccion de una composicion de dosis unica administrable oralmente en un sachet, para tratar disfuncion sexual o aumentar la respuesta sexual en un paciente.
ARP000101511A 1999-04-02 2000-03-31 Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma. AR031067A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/285,048 US6323211B1 (en) 1996-02-02 1999-04-02 Compositions and methods for treating sexual dysfunctions

Publications (1)

Publication Number Publication Date
AR031067A1 true AR031067A1 (es) 2003-09-10

Family

ID=23092519

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101511A AR031067A1 (es) 1999-04-02 2000-03-31 Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma.

Country Status (5)

Country Link
US (1) US6323211B1 (es)
EP (1) EP1164848A4 (es)
AR (1) AR031067A1 (es)
AU (1) AU3877900A (es)
WO (1) WO2000059304A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7371415B1 (en) * 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
AU3221599A (en) * 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
WO2000056328A1 (en) 1999-03-19 2000-09-28 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
AU2001261244B2 (en) * 2000-05-09 2006-08-03 Nitromed, Inc. Infrared thermography and methods of use
US20050171030A1 (en) * 2000-05-26 2005-08-04 Peter Rohdewald Relieving symptoms of erectile dysfunction and attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
IL157734A0 (en) * 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
US20030158184A1 (en) * 2001-12-21 2003-08-21 Garvey David S. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US20090257956A1 (en) * 2002-01-25 2009-10-15 Ramsey Sallis Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation
AU2003209350A1 (en) 2002-01-25 2003-09-02 Modular Properties Ltd Methods and compositions for treating male erectile dysfunction
US20090035221A1 (en) * 2002-01-25 2009-02-05 Ramsey Sallis Methods and Compositions for Treatment of Erectile Dysfunction
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
JP2006514100A (ja) * 2002-10-24 2006-04-27 イーノス・ファーマシューティカルス・インコーポレーテッド 徐放性ｌ−アルギニン製剤並びに製造方法および使用方法
KR20040043996A (ko) * 2002-11-20 2004-05-27 조나겐, 아이엔씨. 남성 발기부전치료를 위한 개선된 조성물
US7214390B2 (en) * 2003-02-07 2007-05-08 Barmensen Labs, Llc Topical compositions for enhancing sexual responsiveness
US20060189695A1 (en) * 2003-06-25 2006-08-24 Cardiovascular Institute, Ltd External preparation for improving coital function
CA2540202A1 (en) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
AU2006249323B2 (en) 2005-05-27 2012-08-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US20070028930A1 (en) * 2005-06-27 2007-02-08 Delithe Natural Products Inc. Active agent and formulations to minimize or alleviate bladder urgency and irritation and/or to enhance sexual function
DE102005053241A1 (de) * 2005-11-08 2007-05-16 Schwabe Willmar Gmbh & Co Extrakte aus der Rinde von Corynanthe-Arten und deren Verwendung sowie diese Extrakte enthaltende Arzneimittel, diätetische Lebensmittel und pharmazeutische Zubereitungen
CA2665689C (en) * 2006-10-04 2015-12-01 Kyowa Hakko Bio Co., Ltd. Glutathione preparation and method for production thereof
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
FR2975007B1 (fr) * 2011-05-12 2014-03-07 Philippe Davioud Lab Composition pour traiter les troubles de la sexualite
CN109260246A (zh) * 2018-09-14 2019-01-25 俞晓彬 一种具有治疗男性性功能障碍的中药贴剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
FR2547501A1 (fr) 1983-06-15 1984-12-21 Opochimiotherapie Lab Excipient effervescent, sans alcalino-terreux, contenant des composes carbonates de l'arginine et un acide, et comprimes effervescents correspondants
US4885173A (en) 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
DK130287D0 (da) * 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
IT1221826B (it) 1988-06-08 1990-07-12 Medico Harvey Srl Centro Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5059603A (en) 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (fr) 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5236904A (en) 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
GB9012469D0 (en) 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
US5399581A (en) 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
DE4117249C2 (de) 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
DK0676964T3 (da) 1991-11-14 2001-02-05 Brigham & Womens Hospital Nitrosylering af enzym-SH-grupper som en terapeutisk modalitet
WO1993012068A1 (en) 1991-12-11 1993-06-24 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5646181A (en) 1992-07-02 1997-07-08 Research Foundation Of State University Of New York Method and compositions for treating impotence
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
EP0611248B1 (en) 1993-02-10 2000-03-22 B.M.R.A. Corporation B.V. Pharmaceutical composition for treating impotence containing an alpha-1-inhibitor and an alpha-2 inhibitor
US5439938A (en) 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
JP3447809B2 (ja) 1994-07-12 2003-09-16 花王株式会社 浴用剤
US5543430A (en) 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5583144A (en) 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5612314A (en) 1995-04-21 1997-03-18 Brigham & Women's Hospital Nitrosylated neuropeptides
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5932538A (en) 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
GB9608408D0 (en) 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
CA2294480C (en) * 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
FR2765483B1 (fr) 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
FR2774593B1 (fr) 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines

Also Published As

Publication number Publication date
AU3877900A (en) 2000-10-23
EP1164848A1 (en) 2002-01-02
US6323211B1 (en) 2001-11-27
EP1164848A4 (en) 2002-06-05
WO2000059304A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
RU2003130058A (ru) Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона
AR059324A2 (es) Una forma solida de dosificacion oral
HU178867B (en) Process for preparing synergetic analgetic composition containing nalbuphine and acetaminophene
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
AR033688A1 (es) Composicion parenteral reconstituible
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
ES2155093T3 (es) Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa).
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
PE20010480A1 (es) PRODUCTOS DE DROGAS ß-CARBOLINE
AR020226A1 (es) Compuestos para la inhibicion de la secrecion de acido gastrico, procesos para su preparacion, formulaciones farmaceuticas y uso de dichos compuestos parapreparar medicamentos
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
SE0201194D0 (sv) New compounds
SE0102055D0 (sv) New Compounds
HUP0301487A2 (hu) Piranon proteáz inhibitorok orális adagolású önemulgeáló formulációi
KR890006228A (ko) 항종양제로서 폴리아민 유도체
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda
IT1252185B (it) Preparazioni farmaceutiche a liberazione programmata
CO5261624A1 (es) Novedosos derivados fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
ATE347357T1 (de) Zusammensetzungen, welche tetracycline enthalten, zur behandlung oder verhinderung von mukositis
GT200000087A (es) Formas polimorfas de un citrato de azabiciclo(2.2.2) octan - 3 - amina y sus composiciones farmaceuticas.
PE20020903A1 (es) Metodo para prevenir la diarrea

Legal Events

Date Code Title Description
FA Abandonment or withdrawal